226 related articles for article (PubMed ID: 19957108)
1. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome.
Reuschenbach M; Kloor M; Morak M; Wentzensen N; Germann A; Garbe Y; Tariverdian M; Findeisen P; Neumaier M; Holinski-Feder E; von Knebel Doeberitz M
Fam Cancer; 2010 Jun; 9(2):173-9. PubMed ID: 19957108
[TBL] [Abstract][Full Text] [Related]
2. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers.
Schwitalle Y; Kloor M; Eiermann S; Linnebacher M; Kienle P; Knaebel HP; Tariverdian M; Benner A; von Knebel Doeberitz M
Gastroenterology; 2008 Apr; 134(4):988-97. PubMed ID: 18395080
[TBL] [Abstract][Full Text] [Related]
3. Recurrent Frameshift Neoantigen Vaccine Elicits Protective Immunity With Reduced Tumor Burden and Improved Overall Survival in a Lynch Syndrome Mouse Model.
Gebert J; Gelincik O; Oezcan-Wahlbrink M; Marshall JD; Hernandez-Sanchez A; Urban K; Long M; Cortes E; Tosti E; Katzenmaier EM; Song Y; Elsaadi A; Deng N; Vilar E; Fuchs V; Nelius N; Yuan YP; Ahadova A; Sei S; Shoemaker RH; Umar A; Wei L; Liu S; Bork P; Edelmann W; von Knebel Doeberitz M; Lipkin SM; Kloor M
Gastroenterology; 2021 Oct; 161(4):1288-1302.e13. PubMed ID: 34224739
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability: an update.
Yamamoto H; Imai K
Arch Toxicol; 2015 Jun; 89(6):899-921. PubMed ID: 25701956
[TBL] [Abstract][Full Text] [Related]
5. [Pathogenesis of microsatellite-unstable colorectal cancer. Evaluation of new diagnostic and therapeutic options].
Kloor M
Pathologe; 2013 Nov; 34 Suppl 2():277-81. PubMed ID: 24196629
[TBL] [Abstract][Full Text] [Related]
6. T cell responses against microsatellite instability-induced frameshift peptides and influence of regulatory T cells in colorectal cancer.
Bauer K; Nelius N; Reuschenbach M; Koch M; Weitz J; Steinert G; Kopitz J; Beckhove P; Tariverdian M; von Knebel Doeberitz M; Kloor M
Cancer Immunol Immunother; 2013 Jan; 62(1):27-37. PubMed ID: 22729559
[TBL] [Abstract][Full Text] [Related]
7. A Frameshift Peptide Neoantigen-Based Vaccine for Mismatch Repair-Deficient Cancers: A Phase I/IIa Clinical Trial.
Kloor M; Reuschenbach M; Pauligk C; Karbach J; Rafiyan MR; Al-Batran SE; Tariverdian M; Jäger E; von Knebel Doeberitz M
Clin Cancer Res; 2020 Sep; 26(17):4503-4510. PubMed ID: 32540851
[TBL] [Abstract][Full Text] [Related]
8. A Genetic Vaccine Encoding Shared Cancer Neoantigens to Treat Tumors with Microsatellite Instability.
Leoni G; D'Alise AM; Cotugno G; Langone F; Garzia I; De Lucia M; Fichera I; Vitale R; Bignone V; Tucci FG; Mori F; Leuzzi A; Di Matteo E; Troise F; Abbate A; Merone R; Ruzza V; Diodoro MG; Yadav M; Gordon-Alonso M; Vanhaver C; Panigada M; Soprana E; Siccardi A; Folgori A; Colloca S; van der Bruggen P; Nicosia A; Lahm A; Catanese MT; Scarselli E
Cancer Res; 2020 Sep; 80(18):3972-3982. PubMed ID: 32690723
[TBL] [Abstract][Full Text] [Related]
9. Correlation between Density of CD8+ T-cell Infiltrate in Microsatellite Unstable Colorectal Cancers and Frameshift Mutations: A Rationale for Personalized Immunotherapy.
Maby P; Tougeron D; Hamieh M; Mlecnik B; Kora H; Bindea G; Angell HK; Fredriksen T; Elie N; Fauquembergue E; Drouet A; Leprince J; Benichou J; Mauillon J; Le Pessot F; Sesboüé R; Tuech JJ; Sabourin JC; Michel P; Frébourg T; Galon J; Latouche JB
Cancer Res; 2015 Sep; 75(17):3446-55. PubMed ID: 26060019
[TBL] [Abstract][Full Text] [Related]
10. The Different Immune Profiles of Normal Colonic Mucosa in Cancer-Free Lynch Syndrome Carriers and Lynch Syndrome Colorectal Cancer Patients.
Bohaumilitzky L; Kluck K; Hüneburg R; Gallon R; Nattermann J; Kirchner M; Kristiansen G; Hommerding O; Pfuderer PL; Wagner L; Echterdiek F; Kösegi S; Müller N; Fischer K; Nelius N; Hartog B; Borthwick G; Busch E; Haag GM; Bläker H; Möslein G; von Knebel Doeberitz M; Seppälä TT; Ahtiainen M; Mecklin JP; Bishop DT; Burn J; Stenzinger A; Budczies J; Kloor M; Ahadova A
Gastroenterology; 2022 Mar; 162(3):907-919.e10. PubMed ID: 34863788
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic peptides generated by frameshift mutations in DNA mismatch repair-deficient cancer cells.
Schwitalle Y; Linnebacher M; Ripberger E; Gebert J; von Knebel Doeberitz M
Cancer Immun; 2004 Nov; 4():14. PubMed ID: 15563124
[TBL] [Abstract][Full Text] [Related]
12. RNF43 is mutated less frequently in Lynch Syndrome compared with sporadic microsatellite unstable colorectal cancers.
Fennell LJ; Clendenning M; McKeone DM; Jamieson SH; Balachandran S; Borowsky J; Liu J; Kawamata F; Bond CE; Rosty C; Burge ME; Buchanan DD; Leggett BA; Whitehall VLJ
Fam Cancer; 2018 Jan; 17(1):63-69. PubMed ID: 28573495
[TBL] [Abstract][Full Text] [Related]
13. Frameshift-derived neoantigens constitute immunotherapeutic targets for patients with microsatellite-instable haematological malignancies: frameshift peptides for treating MSI+ blood cancers.
Maletzki C; Schmidt F; Dirks WG; Schmitt M; Linnebacher M
Eur J Cancer; 2013 Jul; 49(11):2587-95. PubMed ID: 23561850
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability and novel mismatch repair gene mutations in northern Chinese population with hereditary non-polyposis colorectal cancer.
Sheng JQ; Chan TL; Chan YW; Huang JS; Chen JG; Zhang MZ; Guo XL; Mu H; Chan AS; Li SR; Yuen ST; Leung SY
Chin J Dig Dis; 2006; 7(4):197-205. PubMed ID: 17054581
[TBL] [Abstract][Full Text] [Related]
15. Taiwan hospital-based detection of Lynch syndrome distinguishes 2 types of microsatellite instabilities in colorectal cancers.
Chang SC; Lin PC; Yang SH; Wang HS; Liang WY; Lin JK
Surgery; 2010 May; 147(5):720-8. PubMed ID: 20045164
[TBL] [Abstract][Full Text] [Related]
16. Hereditary prostate cancer as a feature of Lynch syndrome.
Bauer CM; Ray AM; Halstead-Nussloch BA; Dekker RG; Raymond VM; Gruber SB; Cooney KA
Fam Cancer; 2011 Mar; 10(1):37-42. PubMed ID: 20872076
[TBL] [Abstract][Full Text] [Related]
17. Extended microsatellite analysis in microsatellite stable, MSH2 and MLH1 mutation-negative HNPCC patients: genetic reclassification and correlation with clinical features.
Schiemann U; Müller-Koch Y; Gross M; Daum J; Lohse P; Baretton G; Muders M; Mussack T; Kopp R; Holinski-Feder E
Digestion; 2004; 69(3):166-76. PubMed ID: 15118395
[TBL] [Abstract][Full Text] [Related]
18. Activating ERBB2/HER2 mutations indicate susceptibility to pan-HER inhibitors in Lynch and Lynch-like colorectal cancer.
Kloth M; Ruesseler V; Engel C; Koenig K; Peifer M; Mariotti E; Kuenstlinger H; Florin A; Rommerscheidt-Fuss U; Koitzsch U; Wodtke C; Ueckeroth F; Holzapfel S; Aretz S; Propping P; Loeffler M; Merkelbach-Bruse S; Odenthal M; Friedrichs N; Heukamp LC; Zander T; Buettner R
Gut; 2016 Aug; 65(8):1296-305. PubMed ID: 26001389
[TBL] [Abstract][Full Text] [Related]
19. TGFBR2-dependent alterations of exosomal cargo and functions in DNA mismatch repair-deficient HCT116 colorectal cancer cells.
Fricke F; Lee J; Michalak M; Warnken U; Hausser I; Suarez-Carmona M; Halama N; Schnölzer M; Kopitz J; Gebert J
Cell Commun Signal; 2017 Apr; 15(1):14. PubMed ID: 28376875
[TBL] [Abstract][Full Text] [Related]
20. High-sensitivity microsatellite instability assessment for the detection of mismatch repair defects in normal tissue of biallelic germline mismatch repair mutation carriers.
González-Acosta M; Marín F; Puliafito B; Bonifaci N; Fernández A; Navarro M; Salvador H; Balaguer F; Iglesias S; Velasco A; Grau Garces E; Moreno V; Gonzalez-Granado LI; Guerra-García P; Ayala R; Florkin B; Kratz C; Ripperger T; Rosenbaum T; Januszkiewicz-Lewandowska D; Azizi AA; Ragab I; Nathrath M; Pander HJ; Lobitz S; Suerink M; Dahan K; Imschweiler T; Demirsoy U; Brunet J; Lázaro C; Rueda D; Wimmer K; Capellá G; Pineda M
J Med Genet; 2020 Apr; 57(4):269-273. PubMed ID: 31494577
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]